Cadila Healthcare Limited Theophylline Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Theophylline Export Records India — #12 Exporter, 11 Shipments, $260.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Theophylline

India Pharmaceutical Trade Intelligence

$15.7M114 Suppliers67 CountriesHS 30049099

ExportsIndia → UNITED STATES46.5%India → SRI LANKA16.2%

#1 Supplier: ALEMBIC PHARMACEUTICALS #1 Buyer: J. KNIPPER

Cadila Healthcare Limited — Theophylline Exporter #12 | $260.5K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Theophylline Exporter Profile

Indian Pharmaceutical Exporter · #12 for Theophylline · $260.5K export value · DGFT Verified

Cadila Healthcare Limited is the #12 Indian exporter of Theophylline with $260.5K in export value and 11 verified shipments. Cadila Healthcare Limited holds a 1.7% market share in Theophylline exports across 2 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Theophylline Export Profile: Buyers & Destinations

Cadila Healthcare Limited Theophylline export treemap — buyers and destination countries | TransData Nexus

Where Does Cadila Healthcare Limited Export Theophylline?

Country	Value	Shipments	Share
SRI LANKA	$330.9K	16	99.3%
KENYA	$2.3K	1	0.7%

Cadila Healthcare Limited exports Theophylline to 2 countries. The largest destination is SRI LANKA accounting for 99.3% of Cadila Healthcare Limited's Theophylline shipments. These destinations reflect Cadila Healthcare Limited's established distribution network and regulatory approvals in key markets.

Who Are the Top Buyers of Theophylline from Cadila Healthcare Limited?

What Theophylline Formulations Does Cadila Healthcare Limited Export?

Product Description / Formulation	Value	Shipments
DERIPHYLLIN RETARD 150MG TABETOPHYLLINE77% & THEOPHYLLINE 23%1X300	$177.4K	5
DERIPHYLLIN RETARD 150MG TAB ETOPHYLLINE 77% & THEOPHYLLINE 23% 1X300	$85.1K	3
DERIPHYLLIN SYRUP 100MLETOPHYLLINE 77%& THEOPHYLLINE 23%100 ML	$26.3K	3
DERIPHYLLIN SYRUP 100ML ETOPHYLLINE 77%& THEOPHYLLINE 23% 100ML	$15.2K	1
DERIPHYLLIN RETARD 300MG TAB ETOPHYLLINE 77% & THEOPHYLLINE 23% 1X100	$13.6K	2
DERIPHYLLIN RETARD 300MG TAB ETOPHYLLINE 77% & THEOPHYLLINE 23%	$13.3K	1
DERIPHYLLIN SYRUP 100ML ETOPHYLLINE 77%& THEOPHYLLINE 23% 1 X 100 ML	$2.3K	1
DERIPHYLLIN RETARD 300MG SAMPLE ETOPHYLLINE 77% & THEOPHYLLINE 23% PHYSICIANSSAMPLE FOR NCV	$0	1

Cadila Healthcare Limited exports 8 distinct Theophylline formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DERIPHYLLIN RETARD 150MG TABETOPHYLLINE77% & THEOPHYLLINE 23 with 5 shipments worth $177.4K.

How Does Cadila Healthcare Limited Compare to Nearest Theophylline Exporters?

Exporters ranked immediately above and below #12 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
10	ANNORA PHARMA PRIVATE LIMITED	$290.4K	10	1	$29.0K
11	SOCOMED PHARMA PRIVATE LIMITED	$281.1K	22	5	$12.8K
12	CADILA HEALTHCARE LIMITED ★	$260.5K	11	2	$23.7K
13	STRIDES PHARMA SCIENCE LIMITED	$150.0K	3	1	$50.0K
14	LAZERHEAD LIFESCIENCES PRIVATE LIMITED	$137.0K	4	1	$34.3K

Cadila Healthcare Limited ranks #12 among 114 Indian Theophylline exporters. Average shipment value of $23.7K compared to the market average of $91.3K. The closest competitors by value are ANNORA PHARMA PRIVATE LIMITED and SOCOMED PHARMA PRIVATE LIMITED.

Which Indian Ports Ship Theophylline Exports?

Port	Shipments	% Share
SAHAR AIR	148	13.4%
DELHI AIR	140	12.6%
DELHI AIR CARGO ACC (INDEL4)	131	11.8%
SAHAR AIR CARGO ACC (INBOM4)	118	10.6%
NHAVA SHEVA SEA (INNSA1)	77	6.9%
JNPT/ NHAVA SHEVA SEA	60	5.4%
BANGALORE ICD (INWFD6)	52	4.7%
Bombay Air	47	4.2%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Theophylline Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Theophylline shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 17 individual customs records matching Cadila Healthcare Limited exporting Theophylline, covering 8 formulations to 2 countries via 2 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 67+ countries, 268+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Theophylline

Theophylline

Cadila Healthcare Limited — Theophylline Exporter Profile

Cadila Healthcare Limited — Theophylline Export Profile: Buyers & Destinations

Where Does Cadila Healthcare Limited Export Theophylline?

Who Are the Top Buyers of Theophylline from Cadila Healthcare Limited?

What Is India's Total Theophylline Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Theophylline Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Theophylline Exporters?

What Theophylline Formulations Does Cadila Healthcare Limited Export?

How Does Cadila Healthcare Limited Compare to Nearest Theophylline Exporters?

Which Indian Ports Ship Theophylline Exports?

What Other Respiratory Products Does Cadila Healthcare Limited Export?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Theophylline Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Theophylline Export Data from Cadila Healthcare Limited

Theophylline Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source

SUNSHINE HEALTHCARE LANKA LIMITED	SRI LANKA	$330.9K	16
GALAXY PHARMACEUTICAL LIMITED	KENYA	$2.3K	1